Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease

Figure 4

Involvement of the TRPV1 channel on the neuroprotective actions of endogenous and synthetic cannabinoids on bNOS expressing amacrine cells. (a) Intravitreal coinjection of the TRPV1 antagonist capsazepine (10⁻⁶ M) with AMPA (42 nmol/eye) + AEA (10⁻⁷ M, ) or 2-AG (b) (10⁻⁷ M, ) or HU-210 (c) (10⁻⁷ M, ) attenuated the neuroprotective effects of the cannabinoid ligands ( compared to CTRL, , compared to AMPA, and , compared to AEA (10⁻⁷ M) or 2-AG (10⁻⁷ M) or HU-210 (10⁻⁷ M), resp.). (d) The TRPV1 channel agonist capsaicin (10⁻⁶–10⁻⁴ M, ) coinjected with AMPA had no neuroprotective effect at any of the doses tested (, compared to CTRL). One-way ANOVA with Tukey’s post hoc analysis was used for the statistical analysis of all data presented in this figure.

(a)

(b)

(c)

(d)